Disclosed herein is a process for producing high-purity gadobutrol, a gadolinium-containing MR contrast agent, in a purity (according to HPLC) of more than 99.7or 99.8 or 99.9% and the use for preparing a pharmaceutical formulation for parenteral administration. The process is carried out using specifically controlled crystallization conditions.
